DSS, Inc. reports developments across a diversified operating platform that includes Product Packaging, Biotechnology, Commercial Lending, and Securities & Investment Management. Company updates commonly address packaging operations, financial results, balance-sheet actions, common-stock offerings, and regulatory or audit disclosures.
News also covers subsidiary activity such as Sentinel Brokers Company, Inc., a FINRA-registered broker-dealer with fixed income trading, equity market-making, and approval to act as an underwriter and selling group member for corporate securities offerings.
DSS, a multinational company, announced a $1 million equity investment in Vivacitas Oncology, a clinical-stage firm focused on difficult-to-treat cancers. This investment, made through DSS Biomedical, highlights DSS's commitment to enhancing human healthcare. Vivacitas's lead candidate, AR-67, shows promise in treating cancers resistant to current therapies, with clinical data indicating potential improvements in progression-free survival for glioblastoma patients while reducing severe side effects. The CEO of DSS expressed optimism about the strategic investment.
Impact BioMedical, a subsidiary of Document Security Systems (NYSE American: DSS), announced a collaboration with Thomas Swan Co. to research Procombin, a plant-based preservation booster. This partnership aims to test Procombin's effectiveness in extending the shelf life of consumer products including personal care and cleaning items. Daryl Thompson emphasized the project’s potential to enhance product quality globally. Thomas Swan, established in 1926, specializes in custom chemical research. The development of Procombin represents a significant step towards sustainable preservation solutions.
Impact BioMedical, a subsidiary of Document Security Systems (NYSE American: DSS), announced the issuance of Patent # 11,033,528 for its antiviral compound Equivir on June 15, 2021. This patent follows the initial patent granted in 2019. Equivir has shown positive pre-clinical results against viral infections including Ebola and Rhinovirus. The company is pursuing a third patent and aims to explore its potential in various antiviral applications, enhancing its intellectual property portfolio.
Impact Biomedical, a subsidiary of Document Security Systems (DSS), announced major updates on its research projects aimed at addressing global challenges in biotechnology. Key collaborations and advancements were highlighted, including the Procombin study to improve antibiotics and the CRST-1 molecule, which shows promising results in cancer treatment. The company is also exploring global licensing for several products, such as Equivir and Linebacker. This strategic focus on innovation positions Impact Biomedical as a potential leader in the biotech industry.
Document Security Systems (DSS) announced the launch of Liquid Value Asset Management Limited (LVAM) through its subsidiary, DSS Financial Management Inc. This fund management company, based in Hong Kong, will focus on algorithmic trading across various financial instruments. The team, including former Societe Generale and Citadel professionals, boasts a track record of 20% annual returns and a Sharpe ratio above 2.0. CEO Frank D. Heuszel expressed confidence in rapidly growing LVAM's trading assets to over $1 billion.
Document Security Systems (DSS) has announced a significant expansion in its investment in American Medical REIT (AMRE) through a $2.6 million share purchase, increasing its ownership from 52% to 99%. This investment will fund the acquisition of Ivy Brook Medical Center in Shelton, Connecticut, a prestigious 40,000 square-foot facility. CEO Frank Heuszel highlighted the resilience of the health services real estate sector, citing nearly 100% rent collection rates compared to pre-COVID levels. DSS aims to leverage its expertise to enhance AMRE's portfolio.
Aegis Capital Corp. acted as the Sole Bookrunner for a $50 million public offering of common stock for Document Security Systems, Inc. (DSS), including the exercise of the over-allotment option. This offering is aimed at securing capital for the company's diverse operations, which encompass brand protection technology, blockchain security, and direct marketing, among others. DSS's model includes strategically spinning out subsidiaries through IPOs, potentially enhancing shareholder value.
Document Security Systems, Inc. (NYSE American: DSS) announced the closing of a public offering generating $50.025 million in gross proceeds. The offering consisted of 29 million shares at $1.50 per share, with an additional 4.35 million shares sold via the underwriters' over-allotment option. These funds will support growth in new business lines, acquisitions, and general corporate needs. The offering was executed under a shelf registration statement effective as of June 7, 2021.
Document Security Systems (DSS) announced that its subsidiary, Impact BioMedical, received a patent from the USPTO for its 3FDB, a revolutionary mosquito repellent technology. This formulation enhances existing repellents like DEET by targeting multiple mosquito receptors to provide superior efficacy. The team discovered its active ingredients in the ghost orchid, which naturally repels mosquitoes. With the mosquito repellent market projected to reach $1.2 billion by 2025, DSS aims to leverage this innovation to save lives and address global health challenges related to mosquito-borne diseases.
Document Security Systems, Inc. (DSS) has priced a public offering of 29 million shares at $1.50 per share, aiming for gross proceeds of approximately $43.5 million. The funds will support the company's expansion into new business lines and cover working capital needs. Additionally, underwriters have an option to purchase up to 15% more shares, potentially raising total proceeds to $50 million. The offering is filed under a shelf registration statement effective June 7, 2021.